{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:19:12Z","timestamp":1792534752146,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11926-018-0751-3","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T09:31:39Z","timestamp":1527672699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Enthesitis: Much More Than Focal Insertion Point Inflammation"],"prefix":"10.1007","volume":"20","author":[{"given":"Abdulla","family":"Watad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Cuthbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"issue":"4","key":"751_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/1529-0131(199804)41:4<694::AID-ART17>3.0.CO;2-#","volume":"41","author":"D McGonagle","year":"1998","unstructured":"McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 1998;41(4):694\u2013700.","journal-title":"Arthritis Rheum"},{"issue":"9134","key":"751_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","volume":"352","author":"D McGonagle","year":"1998","unstructured":"McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352(9134):1137\u201340.","journal-title":"Lancet"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-4419-0298-6_4","volume":"649","author":"M Benjamin","year":"2009","unstructured":"Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol. 2009;649:57\u201370.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"751_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1469-7580.2008.00997.x","volume":"213","author":"HM Shaw","year":"2008","unstructured":"Shaw HM, Vazquez OT, McGonagle D, Bydder G, Santer RM, Benjamin M. Development of the human Achilles tendon enthesis organ. J Anat. 2008;213(6):718\u201324.","journal-title":"J Anat"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.120233","volume":"89","author":"D McGonagle","year":"2012","unstructured":"McGonagle D, Aydin SZ, Tan AL. The synovio-entheseal complex and its role in tendon and capsular associated inflammation. J Rheumatol Suppl. 2012;89:11\u20134.","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"751_CR6","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1002\/art.20566","volume":"50","author":"M Benjamin","year":"2004","unstructured":"Benjamin M, Moriggl B, Brenner E, Emery P, McGonagle D, Redman S. The \u201centhesis organ\u201d concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum. 2004;50(10):3306\u201313.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"751_CR7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.32098\/mltj.03.2014.12","volume":"4","author":"J Apostolakos","year":"2014","unstructured":"Apostolakos J, Durant TJS, Dwyer CR, Russell RP, Weinreb JH, Alaee F, et al. The enthesis: a review of the tendon-to-bone insertion. Muscles Ligaments Tendons J. 2014;4(3):333\u201342.","journal-title":"Muscles Ligaments Tendons J"},{"issue":"7","key":"751_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069\u201376.","journal-title":"Nat Med"},{"issue":"3","key":"751_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1469-7580.2008.00864.x","volume":"212","author":"M Benjamin","year":"2008","unstructured":"Benjamin M, Kaiser E, Milz S. Structure-function relationships in tendons: a review. J Anat. 2008;212(3):211\u201328.","journal-title":"J Anat"},{"issue":"5 Suppl 93","key":"751_CR10","first-page":"S36","volume":"33","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Tan AL. The enthesis in psoriatic arthritis. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S36\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"751_CR11","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.4049\/jimmunol.1401244","volume":"193","author":"H Ahlfors","year":"2014","unstructured":"Ahlfors H, Morrison PJ, Duarte JH, Li Y, Biro J, Tolaini M, et al. IL-22 fate reporter reveals origin and control of IL-22 production in homeostasis and infection. J Immunol. 2014;193(9):4602\u201313.","journal-title":"J Immunol"},{"issue":"12","key":"751_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.22645","volume":"67","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken). 2015;67(12):1739\u201349.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"751_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"751_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/08916934.2014.976630","volume":"48","author":"S Ebihara","year":"2015","unstructured":"Ebihara S, Date F, Dong Y, Ono M. Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity. 2015;48(4):259\u201366.","journal-title":"Autoimmunity"},{"issue":"7","key":"751_CR15","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.38638","volume":"66","author":"H Benham","year":"2014","unstructured":"Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, et al. Interleukin-23 mediates the intestinal response to microbial beta-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66(7):1755\u201367.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"751_CR16","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T, Lienenklaus S, Sandrock I, Oberdorfer L, et al. Interleukin-23-dependent gamma\/delta T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol. 2016;68(10):2476\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"751_CR17","first-page":"2155","volume":"28","author":"D McGonagle","year":"2001","unstructured":"McGonagle D, Stockwin L, Isaacs J, Emery P. An enthesitis based model for the pathogenesis of spondyloarthropathy. Additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol. 2001;28(10):2155\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"751_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5455\/apr.102920121510","volume":"1","author":"DB Horton","year":"2012","unstructured":"Horton DB, Sherry DD, Baldassano RN, Weiss PF. Enthesitis is an extraintestinal manifestation of pediatric inflammatory bowel disease. Ann Paediatr Rheumatol. 2012;1(4):214. https:\/\/doi.org\/10.5455\/apr.102920121510 .","journal-title":"Ann Paediatr Rheumatol"},{"issue":"2","key":"751_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1084\/jem.20070906","volume":"205","author":"M Armaka","year":"2008","unstructured":"Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205(2):331\u20137.","journal-title":"J Exp Med"},{"issue":"3","key":"751_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1074-7613(00)80038-2","volume":"10","author":"D Kontoyiannis","year":"1999","unstructured":"Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on\/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999;10(3):387\u201398.","journal-title":"Immunity"},{"issue":"2","key":"751_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.24260","volume":"60","author":"C Williams-Skipp","year":"2009","unstructured":"Williams-Skipp C, Raman T, Valuck RJ, Watkins H, Palmer BE, Scheinman RI. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum. 2009;60(2):408\u201318.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"751_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1582-4934.2009.00984.x","volume":"15","author":"AF Milia","year":"2011","unstructured":"Milia AF, Ibba-Manneschi L, Manetti M, Benelli G, Generini S, Messerini L, et al. Evidence for the prevention of enthesitis in HLA-B27\/hbeta(2)m transgenic rats treated with a monoclonal antibody against TNF-alpha. J Cell Mol Med. 2011;15(2):270\u20139.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"751_CR23","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"751_CR24","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/annrheumdis-2016-209454","volume":"76","author":"K Wilde De","year":"2017","unstructured":"De Wilde K, Martens A, Lambrecht S, Jacques P, Drennan MB, Debusschere K, et al. A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis. Ann Rheum Dis. 2017;76(3):585\u201392.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"751_CR25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/ng.874","volume":"43","author":"M Matmati","year":"2011","unstructured":"Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet. 2011;43(9):908\u201312.","journal-title":"Nat Genet"},{"issue":"35","key":"751_CR26","doi-asserted-by":"publisher","first-page":"E3669","DOI":"10.1073\/pnas.1405798111","volume":"111","author":"I Khmaladze","year":"2014","unstructured":"Khmaladze I, Kelkka T, Guerard S, Wing K, Pizzolla A, Saxena A, et al. Mannan induces ROS-regulated, IL-17A\u2013dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci U S A. 2014;111(35):E3669\u2013E78.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"751_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","volume":"16","author":"LI Sakkas","year":"2017","unstructured":"Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data. Autoimmun Rev. 2017;16(1):10\u20135.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"751_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2012-202925","volume":"73","author":"F Ciccia","year":"2014","unstructured":"Ciccia F, Accardo-Palumbo A, Rizzo A, Guggino G, Raimondo S, Giardina A, et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis. 2014;73(8):1566\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"751_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/art.39458","volume":"68","author":"AS Kehl","year":"2016","unstructured":"Kehl AS, Corr M, Weisman MH. Enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol (Hoboken, NJ). 2016;68(2):312\u201322.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"2","key":"751_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells\u2014a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145\u20139.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"751_CR31","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/art.40150","volume":"69","author":"RJ Cuthbert","year":"2017","unstructured":"\u2022\u2022 Cuthbert RJ, Fragkakis EM, Dunsmuir R, Li Z, Coles M, Marzo-Ortega H, et al. Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol. 2017;69(9):1816\u201322. This is a very important study that indicates the presence of resident innate lymphocytes in human entheses that may have a pathogrenic role in SpA.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"751_CR32","first-page":"488","volume":"56","author":"AA El-Zayadi","year":"2017","unstructured":"\u2022 El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford). 2017;56(3):488\u201393. This study shows the importance of IL-22 as a key pro-inflammatory cytokine in the SpA group of diseases.","journal-title":"Rheumatology (Oxford)"},{"issue":"Pt 5","key":"751_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1469-7580.2001.19950503.x","volume":"199","author":"M Benjamin","year":"2001","unstructured":"Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat. 2001;199(Pt 5):503\u201326.","journal-title":"J Anat"},{"issue":"2","key":"751_CR34","first-page":"219","volume":"31","author":"F Bandinelli","year":"2013","unstructured":"Bandinelli F, Prignano F, Bonciani D, Bartoli F, Collaku L, Candelieri A, et al. Ultrasound detects occult entheseal involvement in early psoriatic arthritis independently of clinical features and psoriasis severity. Clin Exp Rheumatol. 2013;31(2):219\u201324.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"751_CR35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/acr.21733","volume":"64","author":"JE Freeston","year":"2012","unstructured":"Freeston JE, Coates LC, Helliwell PS, Hensor EM, Wakefield RJ, Emery P, et al. Is there subclinical enthesitis in early psoriatic arthritis? A clinical comparison with power doppler ultrasound. Arthritis Care Res (Hoboken). 2012;64(10):1617\u201321.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"751_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5152\/eurjrheumatol.2015.0075","volume":"2","author":"M Hamdy","year":"2015","unstructured":"Hamdy M, Omar G, Elshereef RR, Ellaban AS, Amin M. Early detection of spondyloarthropathy in patients with psoriasis by using the ultrasonography and magnetic resonance image. Eur J Rheumatol. 2015;2(1):10\u20135.","journal-title":"Eur J Rheumatol"},{"issue":"9","key":"751_CR37","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H","volume":"44","author":"H Marzo-Ortega","year":"2001","unstructured":"Marzo-Ortega H, McGonagle D, O\u2019Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001;44(9):2112\u20137.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"751_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/art.10125","volume":"46","author":"D McGonagle","year":"2002","unstructured":"McGonagle D, Marzo-Ortega H, O\u2019Connor P, Gibbon W, Pease C, Reece R, et al. The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. Arthritis Rheum. 2002;46(2):489\u201393.","journal-title":"Arthritis Rheum"},{"key":"751_CR39","unstructured":"Laura Savage, Mark Goodfield, Elizabeth M.A. Hensor, Paul Emery, McGonagle D. Ultrasonographic improvement of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for chronic plaque psoriasis: a 52-week, prospective, open label, controlled cohort study. Abstract ACR. 2016."},{"issue":"5","key":"751_CR40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"751_CR41","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3899\/jrheum.160116","volume":"43","author":"AM Orbai","year":"2016","unstructured":"Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, et al. Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. J Rheumatol. 2016;43(5):965\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"751_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415\u201329.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"751_CR43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semarthrit.2013.04.005","volume":"43","author":"LI Sakkas","year":"2013","unstructured":"Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43(3):325\u201334.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"751_CR44","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"751_CR45","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"751_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3899\/jrheum.140647","volume":"42","author":"A Kavanaugh","year":"2015","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42(3):479\u201388.","journal-title":"J Rheumatol"},{"issue":"15","key":"751_CR47","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/14656566.2017.1378343","volume":"18","author":"L Costa","year":"2017","unstructured":"Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother. 2017;18(15):1557\u201367.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"751_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","volume":"11","author":"D McGonagle","year":"2015","unstructured":"McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. \u2018MHC-I-opathy\u2019-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol. 2015;11(12):731\u201340.","journal-title":"Nat Rev Rheumatol"},{"issue":"16","key":"751_CR49","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"\u2022 Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525\u201336. This is an important study to show the involvment of JAK signal pathways in PsA and the efficacy of JAKi in the treatment of PsA.","journal-title":"N Engl J Med"},{"issue":"16","key":"751_CR50","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350.","journal-title":"N Engl J Med"},{"key":"751_CR51","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u2013862. This is a review paper that provides an elegant summary of the role of JAK signal pathways in the diverse autoimmune diseases.","DOI":"10.1038\/nrd.2017.201"},{"issue":"9","key":"751_CR52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.it.2010.06.004","volume":"31","author":"S Eyerich","year":"2010","unstructured":"Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C. IL-17 and IL-22: siblings, not twins. Trends Immunol. 2010;31(9):354\u201361.","journal-title":"Trends Immunol"},{"issue":"6","key":"751_CR53","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"751_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-016-0031-5","volume":"3","author":"P Mease","year":"2016","unstructured":"Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3(1):5\u201329.","journal-title":"Rheumatol Ther"},{"issue":"11","key":"751_CR55","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993\u20132003.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"751_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"751_CR57","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"24","key":"751_CR58","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","volume":"370","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"2","key":"751_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1084\/jem.20070906","volume":"205","author":"M Armaka","year":"2008","unstructured":"\u2022 Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205(2):331\u20137. An important clinical study and one of the very few that includes enthesitis as an outcome in the treatment of PsA.","journal-title":"J Exp Med"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0751-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0751-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0751-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T04:45:36Z","timestamp":1720327536000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0751-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0751-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"30 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"41"}}